| Reaction Details |
|---|
 | Report a problem with these data |
| Target | Interleukin-1 receptor-associated kinase 4 |
|---|
| Ligand | BDBM50095952 |
|---|
| Substrate/Competitor | n/a |
|---|
| Meas. Tech. | ChEMBL_1505336 (CHEMBL3595104) |
|---|
| IC50 | >1000±n/a nM |
|---|
| Citation |  Nakajima, Y; Inoue, T; Nakai, K; Mukoyoshi, K; Hamaguchi, H; Hatanaka, K; Sasaki, H; Tanaka, A; Takahashi, F; Kunikawa, S; Usuda, H; Moritomo, A; Higashi, Y; Inami, M; Shirakami, S Synthesis and evaluation of novel 1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives as potent and orally efficacious immunomodulators targeting JAK3. Bioorg Med Chem23:4871-83 (2015) [PubMed] Article |
|---|
| More Info.: | Get all data from this article, Assay Method |
|---|
| |
| Interleukin-1 receptor-associated kinase 4 |
|---|
| Name: | Interleukin-1 receptor-associated kinase 4 |
|---|
| Synonyms: | IRAK-4 | IRAK4 | IRAK4_HUMAN | Interleukin-1 receptor-associated kinase 4 (IRAK-4) | Interleukin-1 receptor-associated kinase 4 (IRAK4) | Renal carcinoma antigen NY-REN-64 |
|---|
| Type: | Protein |
|---|
| Mol. Mass.: | 51519.08 |
|---|
| Organism: | Homo sapiens (Human) |
|---|
| Description: | Q9NWZ3 |
|---|
| Residue: | 460 |
|---|
| Sequence: | MNKPITPSTYVRCLNVGLIRKLSDFIDPQEGWKKLAVAIKKPSGDDRYNQFHIRRFEALL
QTGKSPTSELLFDWGTTNCTVGDLVDLLIQNEFFAPASLLLPDAVPKTANTLPSKEAITV
QQKQMPFCDKDRTLMTPVQNLEQSYMPPDSSSPENKSLEVSDTRFHSFSFYELKNVTNNF
DERPISVGGNKMGEGGFGVVYKGYVNNTTVAVKKLAAMVDITTEELKQQFDQEIKVMAKC
QHENLVELLGFSSDGDDLCLVYVYMPNGSLLDRLSCLDGTPPLSWHMRCKIAQGAANGIN
FLHENHHIHRDIKSANILLDEAFTAKISDFGLARASEKFAQTVMTSRIVGTTAYMAPEAL
RGEITPKSDIYSFGVVLLEIITGLPAVDEHREPQLLLDIKEEIEDEEKTIEDYIDKKMND
ADSTSVEAMYSVASQCLHEKKNKRPDIKKVQQLLQEMTAS
|
|
|
|---|
| BDBM50095952 |
|---|
| n/a |
|---|
| Name | BDBM50095952 |
|---|
| Synonyms: | CHEMBL3593777 |
|---|
| Type | Small organic molecule |
|---|
| Emp. Form. | C19H18FN7O |
|---|
| Mol. Mass. | 379.3909 |
|---|
| SMILES | NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1CCN(C[C@@H]1F)c1ccc(cn1)C#N |r| |
|---|
| Structure | 
|
|---|
Search and Browse
